A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Figure 4

Quantification of the ADCC activity of rituximab using frozen ready-to-use iLite effector cells and CD20⁺ target cells. Frozen RTU iLite effector cells (1.2 × 10⁵ cells/well) and CD20⁺ target cells were thawed rapidly and mixed at the E:T ratio indicated and incubated for 4 hours at 37°C in the presence of increasing concentrations of rituximab prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) and the sequential determination of FL and NL activity. Results are expressed as FL activity in RLU (a) or as fold induction (b) and as NL activity in RLU (c).

(a)

(b)

(c)